United States · Health Care · USD (Millions) · Annual
Reported figures and Equlion model projections for the next 4 years.
Amounts in USD (millions); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for AMICUS THERAPEUTICS, INC.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | |||
|---|---|---|---|---|---|
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 |
| ROE | -11.58% | 16.74% | 11.85% | 10.68% | 10.98% |
|---|---|---|---|---|---|
| ROA | -3.13% | 5.1% | 3.88% | 3.67% | 3.95% |
| Gross Margin | 89.98% | 88.45% | 88.31% | 88.02% | 88.05% |
| Net Margin | -4.27% | 7.19% | 5.29% | 4.96% | 5.27% |
| Total Assets | $949.87M | $1,015.42M | $1,087.10M | $1,158.22M | $1,233.35M |
| Net Income | -$27.11M | $50.11M | $40.84M | $41.19M | $47.22M |